RxDoctor Payments Data

Landon Colling, MD

Ophthalmology · Lynchburg, VANPI 1952517187

Payments from drug & device makers

$1,173in general payments, 2019–2025

Across 49 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$385
  • Genentech USA, Inc.$196
  • Bausch & Lomb Americas Inc.$154
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$107
  • AbbVie$94
  • Novartis$57
  • plus $179 from 7 others

What the payments were for

  • Food & beverage$1,173100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,173 in reported general payments places this provider in the 50th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$3,629,656
Medicare patients
1,788
Services billed
14,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost128$46,181
RestasisCyclosporine40$41,733
Restasis MultidoseCyclosporine28$24,343
CombiganBrimonidine Tartrate/Timolol53$19,829
Latanoprost1,529$11,366
Cyclosporine25$9,106
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol71$8,365
SimbrinzaBrinzolamide/Brimonidine Tart18$6,692
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat358$5,535
Prednisolone Acetate145$4,886
Lotemax SmLoteprednol Etabonate13$3,547
VyzultaLatanoprostene Bunod11$3,539
Brimonidine Tartrate307$2,842
Timolol Maleate392$2,799
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha176$2,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Combigan$94$132,087249 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm$107$3,54713 claims
Bausch & Lomb Americas Inc.Vyzulta$154$3,53911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →